Christoph Stephan1, Hanna-Mari Baldauf2, Joanne Barry3, Frank A Giordano4, Cynthia C Bartholomae4, Annette Haberl1, Markus Bickel1, Manfred Schmidt4, Stephanie Laufs4, Lars Kaderali3, Oliver T Keppler5. 1. Medical Department no. 2, Infectious Diseases Unit, University Hospital Frankfurt, Frankfurt, Germany. 2. Institute of Medical Virology, National Reference Center for Retroviruses, University Hospital Frankfurt, Frankfurt, Germany Department of Infectious Diseases, Virology, University of Heidelberg, Heidelberg, Germany. 3. VIROQUANT Research Group Modeling, Bioquant BQ0026, University of Heidelberg, Heidelberg, Germany Institute for Medical Informatics and Biometry, Technische Universität Dresden, Dresden, Germany. 4. Department of Translational Oncology, National Center for Tumor Diseases and German Cancer Research Center, Heidelberg, Germany. 5. Institute of Medical Virology, National Reference Center for Retroviruses, University Hospital Frankfurt, Frankfurt, Germany Department of Infectious Diseases, Virology, University of Heidelberg, Heidelberg, Germany oliver.keppler@kgu.de.
Abstract
OBJECTIVES: The rapid early-phase decay of plasma HIV-1 RNA during integrase inhibitor-based therapy is not fully understood. The accumulation of biologically active episomal HIV-1 cDNAs, following aborted integration, could contribute to antiviral potency in vivo. METHODS: This prospective, controlled clinical observation study explored raltegravir's impact on the dynamics of HIV-1 RNA in plasma, and concentrations of total HIV-1 cDNA, episomal 2-long terminal repeat (LTR) circles and HIV-1 integrants in peripheral blood mononuclear cells (PBMC). Individuals starting therapy with two nucleoside reverse transcriptase inhibitors plus either raltegravir (raltegravir group; n = 10 patients) or boosted protease inhibitor/non-nucleoside reverse transcriptase inhibitor (control group; n = 10 patients) were followed for 48 weeks. RESULTS: Suppression of HIV-1 RNA (<50 copies/mL) was reached earlier (5/10 versus 0/10 at week 4; 8/10 versus 4/10 at week 12) on raltegravir. Significant total HIV-1 cDNA reductions in PBMC were reached by day 99 and persisted until day 330, with median factors of decrease of 7.2 and 8.9, respectively. Broad inter-individual variations, yet no treatment-associated differences, were noted for HIV-1 cDNA concentrations. Despite reductions in HIV-1 RNA (∼3 log) and total HIV-1 cDNA (∼1 log), concentrations of integrants and 2-LTR circles remained largely unchanged. CONCLUSIONS: These results extend the previously reported early benefit of raltegravir on the decline of plasma viraemia to treatment-naive patients. The modest treatment-associated, yet group-independent, decline in total HIV-1 cDNA load and the lack of significant changes in integrated and episomal HIV-1 cDNA suggest that most integrated DNA is archival and targeting of HIV reservoirs other than PBMC may underlie beneficial effects of raltegravir.
OBJECTIVES: The rapid early-phase decay of plasma HIV-1 RNA during integrase inhibitor-based therapy is not fully understood. The accumulation of biologically active episomal HIV-1 cDNAs, following aborted integration, could contribute to antiviral potency in vivo. METHODS: This prospective, controlled clinical observation study explored raltegravir's impact on the dynamics of HIV-1 RNA in plasma, and concentrations of total HIV-1 cDNA, episomal 2-long terminal repeat (LTR) circles and HIV-1 integrants in peripheral blood mononuclear cells (PBMC). Individuals starting therapy with two nucleoside reverse transcriptase inhibitors plus either raltegravir (raltegravir group; n = 10 patients) or boosted protease inhibitor/non-nucleoside reverse transcriptase inhibitor (control group; n = 10 patients) were followed for 48 weeks. RESULTS: Suppression of HIV-1 RNA (<50 copies/mL) was reached earlier (5/10 versus 0/10 at week 4; 8/10 versus 4/10 at week 12) on raltegravir. Significant total HIV-1 cDNA reductions in PBMC were reached by day 99 and persisted until day 330, with median factors of decrease of 7.2 and 8.9, respectively. Broad inter-individual variations, yet no treatment-associated differences, were noted for HIV-1 cDNA concentrations. Despite reductions in HIV-1 RNA (∼3 log) and total HIV-1 cDNA (∼1 log), concentrations of integrants and 2-LTR circles remained largely unchanged. CONCLUSIONS: These results extend the previously reported early benefit of raltegravir on the decline of plasma viraemia to treatment-naive patients. The modest treatment-associated, yet group-independent, decline in total HIV-1 cDNA load and the lack of significant changes in integrated and episomal HIV-1 cDNA suggest that most integrated DNA is archival and targeting of HIV reservoirs other than PBMC may underlie beneficial effects of raltegravir.
Authors: Ann C Collier; Tae-Wook Chun; Janine Maenza; Robert W Coombs; Kenneth Tapia; Ming Chang; Claire E Stevens; J Shawn Justement; Danielle Murray; Joanne D Stekler; James I Mullins; Sarah E Holte Journal: Biores Open Access Date: 2016-01-01
Authors: Marek Widera; Miriam Dirks; Barbara Bleekmann; Robert Jablonka; Martin Däumer; Hauke Walter; Robert Ehret; Jens Verheyen; Stefan Esser Journal: Med Microbiol Immunol Date: 2017-02-20 Impact factor: 3.402
Authors: Jasmini Alagaratnam; Helen Peters; Kate Francis; Natasha Kay; Yvonne Gilleece; Fionnuala P Finnerty; Rosanna E Grimes; Sarah Parry; Mags Portman; Brenton C Wait; Rimi Shah; Sherie Roedling; David A Hawkins; Sarah Chitty; Liat Sarner; Rebecca Marcus; Anna Hartley; Achyuta V Nori; Melanie Rosenvinge; Graham P Taylor Journal: AIDS Res Ther Date: 2020-07-13 Impact factor: 2.250